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The objective of the study is to investigate the association of interleukin-6 (IL6) promoter
single-nucleotide polymorphisms rs1800797 (-597 G/A) and rs1800796 (-572 G/C) with
obesity or metabolic syndrome in Mexican-Americans.
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Valley, BRHP 1.103, One West University
Blvd, Brownsville, TX 78520, USA. E-mail:
saraswathy.nair@utrgv.edu

Objective

Methods
The rs1800797 and rs1800796 single-nucleotide polymorphisms were genotyped in
Mexican-Americans (n = 437) from South Texas, and results were correlated with measures of obesity and metabolic syndrome including body mass index, waist circumference, blood pressure, cholesterol, triglycerides, glucose, liver enzymes, plasma IL6 and
high-sensitive C-reactive protein (hs-CRP).

Results
Significant associations were found for the rs1800796 variant with increased waist circumference, insulin resistance, lower IL6 levels and higher hs-CRP levels. The
rs1800797 variant showed no associations with metabolic traits but was associated with
higher IL6 levels and lower hs-CRP levels.

Conclusions
Findings in this study support the anti-inflammatory, anti-obesity and glucose homeostatic roles of IL6 in Mexican-American youth.

Keywords: Genetics, inﬂammation, interleukin-6, obesity.

Introduction
Most genetic association studies for obesity are conducted in older populations where epigenetic effects can
result in reduced heritability calculations and distract from
investigating true genetic susceptibility (1). Epigenetics
may be less influential in younger populations where environment has not yet confounded the genetic contribution
to obesity. Studies in obesity-related inflammation are
also generally performed in older age groups, although
some studies in adolescents or younger age groups show
similar obesity associated elevated levels of proinflammatory cytokines, such as tumour necrosis factor
alpha, interleukin-1 beta and interleukin-6 (IL6) (2,3).
Pro-inflammatory cytokines (e.g. IL6) can influence adipocyte function, lipid metabolism, homeostasis, blood
pressure and insulin sensitivity and thus play a major role

in the development of diabetes, atherosclerosis and
cardiovascular diseases (4). However, IL6 can also be
anti-inflammatory, regenerative and homeostatic by controlling acute-phase response and modulating glucose
and liver metabolism (5,6).
Interleukin-6 polymorphisms have been investigated in
many populations for associations with various chronic
diseases (4). For example, single-nucleotide polymorphisms (SNPs) rs1800797 (-597 G/A), rs1800796 (-572
G/C) and rs1800795 (-174 G/C), located in the promoter
region of IL6, have been shown to be associated with
obesity and metabolic traits in different ethnic groups
(Table 1). The rs1800797 SNP is associated with type 2
diabetes in German (7) and metabolic syndrome in French
(8) populations. The rs1800796 SNP is linked with high
insulinogenic index in Danes (10), hyperglycaemia in
Mexicans (11) and hypertension, obesity, type 2 diabetes
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Table 1 Published associations between IL6 SNPs and obesity or metabolic traits
IL6 SNP

First author (Reference)

Ethnicity

Associated genotype

rs1800797
rs1800796

Illig T. (7)
Phillips C.M. (8)
Tanaka C. (9)

German
French
Japanese

GG
GG
GG

Haplotype
*
†
rs1800797/796 /795
Haplotype
†
rs1800797/795

Hamid Y.H. (10)
Ramirez-Lopez G. (11)
Yin Y.W. (12)
Yang X. (13)
Ma H. (14)
Hamid Y.H. (10)
Ramirez-Lopez G. (11)
Zamora-Ginez I. (15)
Saxena M. (16)

Danes
Mexican
Asian
Asian
Asian
Danes
Mexican
Mexican
Indian

CC
CC
GG
GG
GG
GCG
GCG
GG
GG

Associated phenotype
Type 2 diabetes
Metabolic syndrome
Systolic blood pressure and
carotid intima-medial thickness
High insulinogenic index
Hyperglycaemia
Type 2 diabetes
Hypertension and obesity
Hypertension
Type 2 diabetes
Hyperglycaemia and obesity
Type 2 diabetes
Type 2 diabetes

†

*

796 , rs1800796; 795 , rs1800795.
IL6, interleukin-6; SNP, single-nucleotide polymorphism.

and carotid intima-medial thickness in Asians (9,12–14).
These three IL6 promoter SNPs have also been studied
as haplotypes (Table 1). Haplotypes generated from the
rs1800797, rs1800796 and rs1800795 combinations have
been shown to be associated with type 2 diabetes in
Danes (10) and hyperglycaemia and obesity in Mexicans
(11). The GG haplotype for rs1800797 and rs1800795
has been shown to be associated with type 2 diabetes
in Mexicans (15) and Asian Indians (16).
Epidemiological investigations in Mexican-Americans
of South Texas have observed a high prevalence of overweight and obesity (40–50%) (17–19). Non-alcoholic fatty
liver disease prevalence is also higher in this population,
and it is associated with obesity and diabetes (20). Recent
studies have observed elevated levels of liver enzymes in
young Mexican-Americans of South Texas with obesity
and non-alcoholic fatty liver disease (19,20). Based
on these observations and the link between IL6 and
obesity-related traits in other populations, this study
hypothesized genetic associations between IL6 polymorphisms and obesity or metabolic syndrome in MexicanAmericans. This is the first study that investigates genetic
associations between the IL6 promoter SNPs, rs1800797
and rs1800796, with obesity, insulin resistance and metabolic traits including liver enzymes in a cohort of mostly
young (90.2% of cohort population is below 30 years
old) Mexican-Americans of the Rio Grande Valley.

Methods
Subjects
DNA samples, anthropometric measurements and laboratory analyses were obtained from Mexican-American

adolescents and adults residing in the area of Rio Grande
Valley, South Texas. Of the 437 subjects, 394 were
between age of 14 and 30 years (90.2% characterized
as mostly young), and 43 were older than 30 years
(9.8%). Three hundred subjects were between age 14
and 19 years, 94 between age 20 and 30 years, 26
between age 30 and 40 years and 17 older than 40 years.
Characteristics of the study subjects were previously
described by Rentfro et al. (18) and Duran-Gonzalez
et al. (21). Studies were approved by the Institutional
Review Board (University of Texas at Rio Grande Valley).
The studies were performed upon receiving written
informed consents from subjects and, in the case of
adolescents, from their parents. No stipend was provided
to any of the participants.

Anthropometric and metabolic measurements
Individuals 19 years old or younger were categorized as
adolescents, and individuals 20 years old or older were
categorized as adults. Based on Centers for Disease
Control and Prevention growth charts, adolescents with
body mass index (BMI) between 85th and 95th percentile
were considered overweight, and adolescents with BMI
above 95th percentile were considered obese. In adults,
BMI values between 25 and 29.9 kg m2 were considered
overweight, and values equal or above 30 kg m2 were
considered obese (18,21). Waist circumference cut-off
value was the 80th percentile in adolescents and in adults
was above 88 cm in women and 102 cm in men (21).
Homeostatic model assessment of insulin resistance
(HOMA-IR) values equal or above 3.16 were considered
abnormal (18,21). The obesity classifications (overweight
and obese) were coded as abnormal. Blood pressure
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(in adolescents), glucose and triglycerides cut-off values
were defined as in Rentfro et al. (18). In adults, systolic
blood pressure was considered abnormal if it was equal
or above 130 mmHg, and diastolic blood pressure
was considered abnormal if it was equal or above
85 mmHg (22).
Fasting blood samples were drawn and sent to Clinical
Laboratory Improvement Amendments approved clinical
laboratories for metabolic measurements including blood
glucose, triglycerides, cholesterol and liver enzymes
aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Total cholesterol values above
200 mg dL1 were considered abnormal, low-density
lipoprotein cholesterol values greater than or equal to
100 mg dL1 were classified as high and high-density lipoprotein cholesterol values of less than 40 mg dL1
were classified as low (23). The cut-off value for abnormal
liver enzymes (AST and ALT) was 40 U L1 (20). Plasma
levels of IL6 (Merck Millipore, Burlington, MA, USA) and
high-sensitive C-reactive protein (hs-CRP) (Alpha
Diagnostic International, San Antonio, TX, USA) were
measured using ELISA kits as per manufacturer’s instructions from fasting blood samples.

DNA isolation and genotyping
QIAmp DNA Mini Kit (Qiagen, Valencia, CA, USA) was
used to extract DNA from 1 mL of white blood cells.
DNA quantification was conducted using a NanoDrop
spectrophotometer (Thermo Scientific, Waltham, MA,
USA). DNA (50–100 ng well1) was used in genotyping
assays. TaqMan SNP Genotyping Assays were used for
genotyping rs1800797 and rs1800796 in Step One Plus
Real-time PCR system (Applied Biosystems, Carlsbad,
CA, USA).

Statistical analysis
All statistical analyses were performed using PLINK
v.1.07
(http://pngu.mgh.harvard.edu/~purcell/plink).
Hardy–Weinberg equilibrium was used to analyse genotype distribution deviations in the two IL6 SNPs. Linkage
disequilibrium statistics were also performed in PLINK.
Associations of SNPs with obesity were performed using
logistic regression analyses assuming additive, dominant
and recessive models, while associations of SNPs with
metabolic traits were performed using logistic regression
analyses assuming only the additive model. For the all
subjects group, logistic regression analyses for obesity
were adjusted for age and gender, while for metabolic
traits were adjusted for age, gender and waist circumference. Fisher exact test was used to identify frequency of
affected and non-affected alleles for each SNP. Data are
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presented as odds ratios with 95% confidence intervals
with respect to the minor alleles. P-values were obtained
from association analyses, and permutation-P tests were
performed to correct for multiple testing (P-values <0.05
were consider significant). Plasma levels of IL6, hs-CRP
and liver enzymes (AST and ALT) in various genotypic
groups were compared and statistical significance
assessed using Student’s t-tests. Comparisons with all
subjects for which values were available were made, as
well as with outliers removed for IL6 and hs-CRP. Values
above 1.5 times the interquartile range were categorized
as outliers. Table 7 shows data with outliers removed for
IL6 and hs-CRP. Table S1 shows the data including
outliers.

Results
Participants consisted of 437 Mexican-Americans: 291
were female, and 146 were male. Anthropometric and
clinical characteristics of the population are described
in Table 2. Population was mostly young (median
age = 17 years, SD = ± 8.26) and with overweight/obesity
(52.17%) (Table 4). In Mexican-Americans, rs1800797 is
in complete linkage disequilibrium with rs1800795 (D0 = 1
and r2 = 1) and in high linkage disequilibrium (D0 = 1) with
rs1800796 but with different allele frequencies resulting in
a low r2 (r2 = 0.08); therefore, rs1800797 and rs1800796
were selected for genotyping and subsequent association analyses. Four hundred and twenty-nine individuals
were successfully genotyped for rs1800797 and 428 for
rs1800796. However, complete phenotype data on these
individuals varied. Both polymorphisms were in
Hardy–Weinberg equilibrium (rs1800797 P = 0.87;
rs1800796 P = 0.34) (Table 3).
Minor allele frequencies (MAFs) for both SNPs were
compared between subjects with and without obesity
phenotypes categorized by BMI and waist circumference.
Table 4 describes association of SNPs with BMI.
MAFs of rs1800797 and rs1800796 did not differ
significantly between the subjects with or without obesity
(rs1800797 P = 0.41; rs1800796 P = 0.22). There were no
associations found between SNPs and BMI using the
additive (rs1800797 P = 0.78; rs1800796 P = 0.60), dominant (rs1800797 P = 0.29; rs1800796 P = 0.09) or recessive (rs1800797 P = 0.87; rs1800796 P = 0.93) models
(Table 4). Table 5 describes the association of SNPs with
waist circumference. MAF of rs1800797 did not differ
significantly between subjects with or without central
obesity (P = 0.17), and no associations with waist circumference were found for rs1800797 using the additive
(P = 0.79), dominant (P = 0.09) or recessive (P = 0.64)
models (Table 5). However, frequency of the rs1800796
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Table 2 Anthropometric and clinical characteristics of Mexican-Americans studied
Characteristics

Subjects with phenotype data (n)

Median ± SD

Q1/Q3

Min/Max

Age (years)

All subjects (437)*
Female (291)
Male (146)
All subjects (436)
Female (290)
Male (146)
All subjects (436)
Female (290)
Male (146)
All subjects (437)
Female (291)
Male (146)
All subjects (437)
Female (291)
Male (146)
All subjects (374)
Female (246)
Male (128)
All subjects (230)
Female (153)
Male (77)
All subjects (230)
Female (153)
Male (77)
All subjects (350)
Female (231)
Male (119)
All subjects (349)
Female (230)
Male (119)
All subjects (350)
Female (231)
Male (119)
All subjects (350)
Female (231)
Male (119)
All subjects (416)
Female (276)
Male (140)
All subjects (128)
Female (84)
Male (44)
All subjects (267)
Female (171)
Male (96)

17 ± 8.26
17 ± 8.70
17 ± 7.29
24.94 ± 6.55
24.56 ± 6.51
25.91 ± 6.64
83 ± 16.83
81.75 ± 15.6
85.3 ± 18.92
110 ± 12.29
110 ± 11.38
116 ± 13.26
69 ± 9.74
69 ± 9.34
70 ± 10.27
2.05 ± 2.87
2.15 ± 3.18
1.86 ± 2.16
21 ± 16.16
19 ± 17.75
25 ± 12.69
33 ± 18.73
31 ± 18.42
36 ± 18.86
149 ± 34.88
147 ± 37.24
151 ± 29.89
68 ± 51.12
64.5 ± 43.64
72 ± 62.16
46 ± 11.85
47 ± 11.86
44 ± 11.5
86.5 ± 25.52
86 ± 26.53
88.4 ± 23.53
90 ± 16.76
89 ± 16.07
92 ± 18.14
3.68 ± 22.21
3.58 ± 18.83
4.17 ± 27.09
0.66 ± 4.93
0.76 ± 5.92
0.53 ± 1.95

15/21
15/22
15/20
22.29/29.87
22.2/29.56
22.51/30.23
75.5/95.63
75/94
77.63/100.5
101/120
100.5/115.5
104/123
63/76
63/74
66/78.75
1.21/3.39
1.36/3.24
1.09/3.44
16/28
15/26.25
18/32
28/39
28/35
33/44
131/171
132/171
130/171.5
48/95
46/92.75
52/111.5
40/55
41/56
38/53
72/103.85
72/103
72.8/106
83.06/96.04
83/95.25
85/97
1.52/14.98
1.6/10.43
1.46/27.01
0.35/1.77
0.35/2.23
0.35/1.27

14/60
14/60
14/54
15.68/55.24
17.17/53.13
15.68/55.24
30/167
40.5/167
30/160
85/156
85/153
85/156
40/97
40/96
45/97
0.02/36.89
0.13/36.89
0.02/12.53
7/157
7/157
12/68
2.4/164
2.4/162
21/164
81/460
89/460
81/230
18/403
25/281
18/403
14/97
14/97
24/89
38/211
38/211
45/163.2
43.06/265.95
43/228
65/266
0.18/125.1
0.2/99.19
0.18/125.1
0.11/57.42
0.16/57.42
0.11/14.8

2

BMI (kg m )

WC (cm)

SBP (mmHg)

DBP (mmHg)

HOMA-IR

1

AST (U L )

1

ALT (U L )

1

Cholesterol (mg dL )

1

Triglycerides (mg dL )

1

HDL (mg dL )

1

LDL (mg dL )

1

Glucose (mg dL )

1

Plasma IL6 (pg mL )

1

hs-CRP (mg L )

*Of the 437 subjects, 394 were between age 14 and 30 years (90.2% characterized as mostly young), and 43 were older than 30 years (9.8%).
Three hundred subjects were between age 14 and 19 years, 94 between age 20 and 30 years, 26 between age 30 and 40 years and 17 older
than 40 years.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol;
HOMA-IR, homeostasis model assessment of insulin resistance; hs-CRP, high-sensitive C-reactive protein; IL6, interleukin-6; LDL, low-density
lipoprotein cholesterol; Max, maximum values; Min, minimum values; SBP, systolic blood pressure; SD, standard deviation; Q1, 1st quartile; Q3,
3rd quartile; WC, waist circumference.

minor allele (C-allele) was significantly higher in subjects
with central obesity (P = 0.02; permutation P-value = 0.04),
and a significant association between rs1800796 and

waist circumference under the dominant model (CC = CG
vs. GG P = 0.01; permutation P-value = 0.03) was
observed (Table 5).
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Table 3 Alleles, allele frequencies and HWE calculations for rs1800797 and rs1800796

SNP

M/m alleles

rs1800797
rs1800796

G/A
G/C

M/M (%)

M/m (%)

m/m (%)

MAF

HWE
P-value

294 (68.53)
225 (52.57)

122 (28.44)
165 (38.55)

13 (3.03)
38 (8.88)

0.17
0.28

0.87
0.34

HWE, Hardy–Weinberg equilibrium; M, major allele; m, minor allele; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
Table 4 Association of SNPs with the phenotypes of obesity categorized by body mass index

SNP
rs1800797

rs1800796

Test
MAF (A-allele)
Additive model
Dominant model
AA + AG vs. GG
Recessive model
AA vs. AG + GG
MAF (C-allele)
Additive model
Dominant model
CC + CG vs. GG
Recessive model
CC vs. CG + GG

Non-obese
phenotype (n = 204)

Overweight/obese
phenotype (n = 221)

OR
(95% CI)

P-value

Permutation
P-value

0.18

0.16

69/135

65/156

0.85
0.92 (0.51–1.67)
0.80 (0.53–1.21)

0.41
0.78
0.29

0.63
0.95
0.50

6/198

6/215

0.90 (0.28–2.94)

0.87

0.98

0.26

0.30

89/115

113/108

1.21
1.10 (0.77–1.56)
1.41 (0.95–2.07)

0.22
0.60
0.09

0.38
0.84
0.17

18/186

20/201

1.03 (0.52–2.04)

0.93

1.0

Associations were adjusted for age and gender.
CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.
Table 5 Association of SNPs with the phenotypes of obesity categorized by waist circumference

SNP
rs1800797

SNP
rs1800796

Non-centrally obese
phenotype (n = 208)

Centrally obese
phenotype (n = 217)

OR
(95% CI)

P-value

Permutation
P-value

0.19

0.15

74/134

60/157

0.78
1.08 (0.60–1.95)
0.70 (0.46–1.05)

0.17
0.79
0.09

0.31
0.95
0.17

5/203

7/210

1.32 (0.41–4.25)

0.64

0.90

Test

Non-centrally obese
phenotype (n = 210)

Centrally obese
phenotype (n = 215)

OR
(95% CI)

P-value

Permutation
P-value

MAF (C-allele)
Additive model
Dominant model
CC + CG vs. GG
Recessive model
CC vs. CG + GG

0.25

0.32

87/123

115/100

1.44
1.29 (0.91–1.83)
1.62 (1.11–2.39)

0.02
0.15
0.01

0.04
0.26
0.03

16/194

22/193

1.37 (0.70–2.69)

0.36

0.59

Test
MAF (A-allele)
Additive model
Dominant model
AA + AG vs. GG
Recessive model
AA vs. AG + GG

Associations were adjusted for age and gender.
CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism. Bolded P-values <0.05, and
statistically significant.

Associations between rs1800797 and rs1800796 and
several metabolic traits were investigated in all subjects,
as well as in subjects separated by gender (Table 6). Metabolic traits included systolic and diastolic blood pressure, HOMA-IR, liver enzymes (AST and ALT), total
cholesterol, triglycerides, high-density and low-density

lipoproteins and glucose. No associations were found
between rs1800797 and metabolic traits in all subjects
or men and women separately (Table 6). For rs1800796,
there were no associations for most of the metabolic
traits except for HOMA-IR, when all subjects were
considered and for female subjects separately

© 2017 The Authors
Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice

0.28
0.37
1.0

HOMA-IR
All subjects (363)
Female (236)
Male (127)

*

7.09e005 (0– )
*
6.96e005 (0– )

1

HDL (mg dL )
All subjects (338)
Female (220)

*

0.0001 (0– )
*
0.0001 (0– )
NA

1

Triglycerides (mg dL )
All subjects (337)
Female (219)
Male (118)

1.0
1.0

1.0
0.99
NA

1.0
1.0
NA

*

5.07e005 (0– )
*
6.03e005 (0– )
NA

Cholesterol (mg dL )
All subjects (338)
Female (220)
Male (118)

1.0
1.0

1.0
0.98
1.0

1.0
1.0
1.0

1.0
1.0
1.0

1.0
0.99
1.0

OR (95% CI)

1

HDL (mg dL )
All subjects (341)
Female (223)

1

Triglycerides (mg dL )
All subjects (340)
Female (222)
Male (118)

1

Cholesterol (mg dL )
All subjects (341)
Female (223)
Male (118)

1.16 (0.70–1.91)
1.23 (0.66–2.32)

*

0.0001 (0– )
*
0.0001 (0– )
*
0.0001 (0– )

1.0 (0.46–2.15)
0.79 (0.30–2.08)
2.03 (0.56–7.34)

1

Alanine aminotransferase (U L )
All subjects (228)
0.77 (0.25–2.35)
Female (151)
0.83 (0.27–2.63)
*
Male (77)
0.0001 (0– )

1

0.35 (0.16–0.77)
0.22 (0.06–0.84)
0.68 (0.23–2.01)

Aspartate aminotransferase (U L )
All subjects (228)
1.12 (0.33–3.87)
Female (151)
1.31 (0.35–4.98)
*
Male (77)
0.0001 (0– )

HOMA-IR
All subjects (361)
Female (234)
Male (127)

Diastolic blood pressure (mmHg)
All subjects (423)
1.31 (0.65–2.62)
Female (279)
0.75 (0.23–2.4)
Male (144)
2.25 (0.84–5.98)

Systolic blood pressure (mmHg)
All subjects (423)
0.92 (0.42–2.04)
Female (279)
0.98 (0.30–3.26)
Male (144)
0.73 (0.21–2.54)

Metabolic traits (n)

0.57
0.51

1.0
1.0
1.0

1.0
0.63
0.28

0.65
0.76
1.0

0.85
0.69
1.0

0.009
0.03
0.49

0.45
0.63
0.10

0.84
0.98
0.63

P-value

0.81
0.64

0.83
0.54
0.40

0.94
0.65
0.12

0.71
0.78
0.96

0.66
0.47
0.91

0.009
0.03
0.54

0.54
0.59
0.08

0.87
0.92
0.46

Permutation
P-value

K. Boeta-Lopez et al.

1

1.0
1.0
NA

Alanine aminotransferase (U L )
*
All subjects (220)
7.93e005 (0– )
*
Female (144)
7.78e005 (0– )
Male (76)
NA

1

1.0
1.0
NA

1

Aspartate aminotransferase (U L )
*
All subjects (220)
0.0001 (0– )
*
Female (144)
0.0001 (0– )
Male (76)
NA

0.48
0.60
1.0

0.88
0.56
1.0

0.90
0.88
1.0

Permutation
P-value

rs1800796

IL6 SNPs in obesity and metabolic syndrome

0.55 (0.18–1.64)
0.61 (0.2–1.8)
*
6.1e005 (0– )

0.85
0.56
1.0

Diastolic blood pressure (mmHg)
All subjects (424)
1.13 (0.34–3.76)
Female (279)
1.43 (0.43–4.73)
*
Male (145)
0.0001 (0– )

P-value
0.87
0.90
1.0

OR (95% CI)

Systolic blood pressure (mmHg)
All subjects (424)
0.89 (0.24–3.31)
Female (279)
0.91 (0.22–3.80)
*
Male (145)
0.0001 (0– )

Metabolic traits (n)

rs1800797

Table 6 Association of SNPs with metabolic traits
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1.0
1.0
1.0
*

0.0001 (0– )
*
0.0001 (0– )
*
0.0003 (0– )
0.45
0.40
0.95
1.63 (0.44–5.97)
1.78 (0.48–6.61)
*
0.0002 (0– )

1

1

Glucose (mg dL )
All subjects (403)
Female (264)
Male (139)

0.46
0.39
1.0

1

Glucose (mg dL )
All subjects (402)
Female (264)
Male (138)

1.09 (0.72–1.64)
1.13 (0.69–1.87)
0.99 (0.45–2.19)
1.0
0.99
1.0
1.05 (0.49–2.28)
1.06 (0.48–2.32)
NA

0.90
0.89
NA

1

LDL (mg dL )
All subjects (341)
Female (223)
Male (118)
LDL (mg dL )
All subjects (338)
Female (220)
Male (118)

P-values for the all subjects group were adjusted for age, gender and waist circumference. P-values for female and male subjects separately were adjusted for age and waist circumference. NA,
frequency of the allele is less than 5.
*Infinity.
CI, confidence interval; HDL, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein cholesterol; OR, odds ratio; SNP,
single-nucleotide polymorphism. Bolded P values are statistically significant (< 0.05).

0.90
0.83
0.95
0.70
0.63
0.97

0.71
0.74
0.86 (0.36–2.07)
Male (118)
1.0
NA
NA
Male (118)

0.76
0.68
0.89
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(P = 0.009 and 0.03, respectively; Table 6). In male
subjects, no associations were found between
rs1800796 and any metabolic trait.
Plasma IL6, hs-CRP and liver enzymes (AST and ALT)
levels were compared between genotypes for each SNP
(Table 7 and Figures 1 and 2). Genotypes were combined
because the numbers of the minor allele homozygotes for
both SNPs were low compared with other genotypes. For
rs1800797, plasma IL6 levels did not differ significantly
between A-allele homozygotes when compared with
G-carriers (AA vs. GG + AG P = 0.48). However, plasma
IL6 levels were significantly higher in rs1800797
A-carriers when compared with G-allele homozygotes
(AA + AG vs. GG P = 0.002) (Table 7 and Figure 1A). For
rs1800796, plasma IL6 was significantly lower in C-allele
homozygotes when compared with G-carriers (CC vs.
GG + CG P = 6.6e07), but it did not differ in C-carriers
when compared with G-allele homozygotes (CC + CG
vs. GG P = 0.33) (Table 7 and Figure 1B).
The inflammation marker, hs-CRP, did not differ between rs1800797 A-homozygotes and G-carriers (AA vs.
GG + AG P = 0.48), but levels were significantly lower in
A-carriers when compared with G-homozygotes (AA + AG
vs. GG P = 0.04) (Table 7 and Figure 1A). For rs1800796,
hs-CRP did not differ between C-homozygotes and Gcarriers (CC vs. GG + CG P = 0.10), but it was significantly
higher in C-carriers when compared with G-homozygotes
(CC + CG vs. GG P = 0.01) (Table 7 and Figure 1B).
Although AST and ALT liver enzymes did not differ
significantly when genotypic groups were compared, a
modest increase in both enzymes was observed for each
SNP’s risk allele for obesity and metabolic traits (Table 7
and Figure 2). For rs1800797, higher AST and ALT values
were found in G-carriers (Table 7 and Figure 2A), whereas
for rs1800796, higher values were found in C-carriers
(Table 7 and Figure 2B).

Discussion
In this study, association analyses assuming additive,
dominant and recessive effects of rs1800797 G-allele
did not show any significant associations with obesity
(categorized by BMI and waist circumference) and metabolic traits. The rs1800797 SNP has not been associated
with metabolic syndrome and diabetes as much as the
rs1800795 SNP (16); however, some studies have
reported the contribution of rs1800797 G-allele to the
development of metabolic syndrome and diabetes, but
not the A-allele (7,8). In this study, despite the lack of
statistical significance, frequency of rs1800797 A-allele
was slightly higher among individuals without obesity.
Plasma IL6 levels were significantly higher, and hs-CRP
levels were significantly lower in A-allele carriers than in
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Table 7 Association of SNPs’ genotypes with plasma IL6, hs-CRP and liver enzymes levels
SNP and
genotypes

Trait
1

Plasma IL6 (pg mL )

1

hs-CRP (mg L )

1

AST (U L )

1

ALT (U L )

rs1800797
AA
AG
GG
rs1800796
CC
CG
GG
rs1800797
AA
AG
GG
rs1800796
CC
CG
GG
rs1800797
AA
AG
GG
rs1800796
CC
CG
GG
rs1800797
AA
AG
GG
rs1800796
CC
CG
GG

n

Mean ± SD

Genotypic combination

P-value

3
31
69

9.19 ± 5.06
12.61 ± 15.05
3.97 ± 4.67

AA vs. GG + AG
AA + AG vs. GG

0.48
0.002

12
45
48

1.97 ± 1.07
6.33 ± 7.59
6.87 ± 8.24

CC vs. GG + CG
CC + CG vs. GG

6.6e07
0.33

3
60
156

0.77 ± 0.01
0.67 ± 0.53
0.86 ± 0.73

AA vs. GG + AG AA +
AG vs. GG

0.48
0.04

22
89
112

1.34 ± 1.56
0.86 ± 0.68
0.69 ± 0.55

CC vs. GG + CG
CC + CG vs. GG

0.10
0.01

6
69
148

23.83 ± 4.31
24.80 ± 12.86
24.51 ± 15.04

AA vs. GG + AG
AA + AG vs. GG

0.71
0.91

21
94
116

27.57 ± 30.59
22.82 ± 10.12
25.47 ± 16.30

CC vs. GG + CG
CC + CG vs. GG

0.63
0.40

6
69
148

34.50 ± 5.54
37.54 ± 20.45
35.91 ± 15.52

AA vs. GG + AG
AA + AG vs. GG

0.47
0.60

21
94
116

37.43 ± 24.29
37.37 ± 19.78
36.05 ± 16.65

CC vs. GG + CG
CC + CG vs. GG

0.89
0.59

Plasma levels of IL6, hs-CRP and liver enzymes (AST and ALT) were compared between various genotype combinations for each SNP.
Student’s t-tests were used to assess statistical significance. IL6 and hs-CRP outliers were removed from the associations. Table S1 shows
the data including outliers. Values above 1.5 times the interquartile range were categorized as outliers.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; hs-CRP, high-sensitive C-reactive protein; IL6, interleukin-6; SD, standard
deviation; SNP, single-nucleotide polymorphism. Bolded P values are statistically significant (< 0.05).

GG-homozygotes, suggesting a possible protective
effect of rs1800797 A-allele against obesity and inflammation in this mostly young Mexican-American cohort.
Findings of this study also demonstrate the possible
role of rs1800796 in central obesity and insulin
resistance in young Mexican-Americans. In this study,
presence of rs1800796 C-allele was higher among subjects with increased waist circumference. This result is
in accordance with a study performed in non-Hispanic
whites where waist-to-hip ratio was significantly higher
in postmenopausal women carrying the C-allele (24). A
Caucasian study associated rs1800796 C-allele with metabolic syndrome, although it did not find an association
with waist circumference (25). Also, two studies performed in Caucasians showed associations between

rs1800796 and obesity. In one of the reports, the
rs1800796 C-allele was shown to be associated with obesity in children (26), and in the other study, they observed
that pregnant women who carry the rs1800796 G-allele
were protected from gestational weight gain (27). However, a study performed in a Dutch cohort observed
smaller waist circumference in rs1800796-CC individuals
compared with G-carriers (28). A Mexican study found
that the rs1800797-A/rs1800796-G/rs1800795-C haplotype was associated with lower prevalence of diabetes
(29), which suggests that the rs1800796 G-allele could
possibly contribute to the protection against developing
type 2 diabetes in Mexicans. A joint analysis including
eight studies of mostly Caucasians did not find an association with the rs1800796 C-allele and diabetes (25), where
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A

P=0.002

Liver enzyme concentration (U/L)

A
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Plasma IL6 (pg/ml)

30.00
25.00
20.00
15.00
10.00
5.00
0.00
Mean

AA (n=3)
9.19

AG (n=31)
12.61

GG (n=69)
3.97
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180
160
140
120
100
80
60
40
20
0

rs1800797

AA(n=6) AG (n=69) GG (n=148) AA(n=6) AG (n=69) GG (n=148)
AST

ALT
rs1800797

P=0.04

1.80

hs-CRP (mg/L)

1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
Mean

AA (n=3)
0.77

AG (n=60)
0.67

GG (n=156)
0.86

rs1800797

B
Plasma IL6 (pg/ml)

14.00
12.00
10.00
8.00
6.00
4.00
2.00

Mean

CC (n=12)
1.97

CG (n=45)
6.33

GG (n=48)
6.87

rs1800796

P=0.01

3.50
3.00
hs-CRP (mg/L)

160
140
120
100
80
60
40
20
0

CC (n=21) CG (n=94) GG (n=116) CC (n=21) CG (n=94) GG (n=116)
ALT
rs1800796

16.00

0.00

180

AST

P=6.6 e-07

18.00

Liver enzyme concentration (U/L)

B

1.60

2.50

Figure 2 Comparison of liver enzyme (aspartate aminotransferase
[AST] and alanine aminotransferase [ALT]) levels for each interleukin-6 (IL6) single-nucleotide polymorphism genotype. A. Liver
enzymes were compared between rs1800797 genotypes. Levels of
liver enzymes did not differ between rs1800797 genotypes, but a
trend for higher plasma levels of liver enzymes was observed in
rs1800797 GG (trend for higher hs-CRP and lower IL6) genotypes.
B. Liver enzymes were compared between rs1800796 genotypes.
Plasma levels of liver enzymes did not differ between rs1800796
genotypes, but a trend of higher plasma levels of liver enzymes was
observed in rs1800796 C (risk allele for waist circumference, homeostasis model assessment of insulin resistance, higher hs-CRP and
lower IL6)-carriers. White circles refer to outliers; black circles refer
to mean.

2.00
1.50
1.00
0.50
0.00
Mean

CC (n=22)
1.34

CG (=89)
0.86

GG (n=112)
0.69

rs1800796

Figure 1 Comparison of mean plasma interleukin-6 (IL6) and highsensitive C-reactive protein (hs-CRP) levels between genotypes for
each single-nucleotide polymorphism. A. Plasma IL6 and hs-CRP
levels were compared between rs1800797 genotypes. Plasma IL6
was significantly higher in rs1800797 A (protective allele against obesity and metabolic traits)-carriers than in G-homozygotes (P = 0.002),
and hs-CRP was significantly lower in rs1800797 A-carriers than in
G-homozygotes (P = 0.04). B. Plasma IL6 and hs-CRP levels were
compared between rs1800796 genotypes. Plasma IL6 was significantly lower in rs1800796 C (risk allele for obesity and metabolic
traits)-homozygotes than in G-carriers (P = 6.6e07), and hs-CRP
was significantly higher in C-carriers than in G-homozygous
(P = 0.01).

BMI was included as a covariate instead of waist circumference. The association of rs1800796 C-allele with risk
for obesity and type 2 diabetes has thus been inconsistent across ethnicities. In this study, however, increased
waist circumference is associated with the rs1800796
C-allele, and because waist circumference has been
classified as a better predictor of obesity, insulin resistance and type 2 diabetes in Mexican-Americans (30), it
was included as a covariate in the analyses of IL6 SNP
associations with metabolic traits. The rs1800796 C-allele
was also found to be associated with higher HOMA-IR
(a surrogate measure of insulin resistance) when analyses
were conducted in all subjects (male and female) and in
female subjects separately. Thus, this study correlates
the rs1800796 C-allele with increased central obesity
and insulin resistance, two important indicators of
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type 2 diabetes and highly heritable among MexicanAmericans (31).
Elevated levels of IL6 are typically associated with
obesity-related inflammation and type 2 diabetes in adolescents and adults with obesity (2,3). One recent study
found higher promoter activity of the rs1800796 G-allele
compared with the C-allele (32). Interestingly, in this
study, rs1800796-CC homozygotes had lower plasma
IL6 levels when compared with G-allele carriers. Additionally, rs1800796 C-allele carriers were found to express
higher hs-CRP levels, a marker of acute immune response (inflammation) in liver, than G-allele homozygotes,
and liver enzymes AST and ALT trended towards being
elevated in rs1800796 C-carriers. This suggests that in
young Mexican-Americans, rs1800796 C-allele carriers
with lower levels of IL6 have a higher risk for obesity associated inflammation and metabolic disturbances such as
insulin resistance and liver inflammation.
There is significant evidence showing that IL6 has antiinflammatory, anti-obesogenic and glucose homeostatic
functions. For example, the development of obesity, hepatic insulin resistance, liver inflammation and damage,
insulin and glucose intolerance and mitochondrial dysfunctions was observed in high fat diet-fed IL6-deficient
mice when compared with control mice (33). Another
study observed an increase in body fat, body weight, triglycerides, very-low-density lipoprotein cholesterol and
impaired glucose elimination in mice lacking the IL6 gene
(34). In addition, body weight decreased after intraperitoneal and/or intracerebroventricular IL6 injections in IL6
knockout mice (34) and wild-type rats (35). Disruption of
the IL6 anti-inflammatory signalling in insulin sensitive tissues was present in myeloid cells IL6 receptor inactivated
mice, leading to insulin resistance (34). A human study
supported the animal studies by observing higher cerebrospinal IL6 levels in subjects without obesity than in
subjects with obesity (36). IL6 has been shown to play a
homeostatic role in muscle through an acute exercise response. In this response, there is an increase in plasma
IL6 levels, IL6 mRNA in adipose tissue and IL6 mRNA
and protein content in the exercised skeletal muscle,
without causing muscle damage (37). Exercise-induced
IL6 acts as an anti-inflammatory cytokine by increasing
cortisol, lipolysis, catecholamine, IL-1 receptor antagonist, IL-10 and CRP (which contributes to the increase
of IL-1RA) to regulate metabolic and energy homeostasis
during exercise (37,38).
A normal homeostatic response of tissues to increased
inflammatory factors (caused by elevated reactive oxygen
species or hypoxia in expanding adipose tissue) may be
an initial acute response of elevated IL6, which in turn
up-regulates anti-inflammatory molecules (such as cortisol, IL-1RA, IL-4 and IL-10) in insulin sensitive tissues or
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brain regulating obesity and is associated with metabolic
perturbations (36). If this normal acute response of IL6 to
inflammation is suppressed or lowered (as in rs1800796CC genotypes) in youth, it may lead to unchecked increase in waist circumference and insulin resistance.
However, in youths with the rs1800797-GG genotype,
the homeostatic response of IL6 in checking inflammation
may be one of the protective factors against metabolic
consequences of obesity.
However, IL6 resistance may underlie chronic obesityrelated inflammation with increased plasma levels of IL6
in adolescents and adults. O’Connor et al. (39) were the
first one to demonstrate dysfunctional activity of IL-4, an
anti-inflammatory cytokine, in type 2 diabetes conditions
and suggested the development of cytokine resistance
to IL-4 in type 2 diabetes, concluding that impaired suppression of inflammation by anti-inflammatory cytokines
is present in type 2 diabetes. They observed that after
IL-4 treatment, macrophages from obese/diabetic mice
failed to express anti-inflammatory cytokines (IL-1RA
and IL-1R2), and induction of IRS-2, mediator of IL-4
response, was significantly reduced in obese/diabetic
macrophages when compared with controls (39).
Although IL6 resistance was not studied by O’Connor
et al. (39), it is entirely plausible that IL6 resistance is
associated with chronic obesity and insulin resistance.
Interleukin-6 changes its macrophage induction from
anti-inflammatory (M2) macrophages in lean individuals
to pro-inflammatory (M1) macrophages in individuals with
obesity (40). In younger individuals with overweight (but
not yet with obesity), the initial acute homeostatic IL6
induction of anti-inflammatory M2 macrophages may
help to prevent further increase in adiposity and/or metabolic perturbations. This initial protective M2 response
may be absent or weak in rs1800796-CC genotype
carriers, with lower IL6 levels. However, in carriers of
rs1800796-GG genotype, while this phenotype may be
protective initially, if obesity/morbid obesity-associated
chronic inflammation develops (with elevated plasma IL6
levels and IL6 resistance), M2 anti-inflammatory response
may no longer be induced by IL6.
In this study, although 52.17% of the subjects had
obesity, only 27.6% had insulin resistance. Thus, a relatively metabolically healthy and young population
(90.2% below 30 years) in which it may be easier to tease
out genetic susceptibility without being influenced by environmental factors such as ageing was studied (1). The
study showed that the rs1800796 C-allele is associated
with central obesity and insulin resistance, whereas
rs1800797 A-allele may be protective against obesity in
a young Mexican-American cohort from the Rio Grande
Valley. Data from this study support the hypothesis that
IL6 plays an anti-inflammatory homeostatic role in obesity
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and metabolic diseases in a young Mexican-American
population. The limitations of the study are the small sample size, incomplete metabolic, clinical and IL6/hs-CRP
data on all genotyped samples, as well as lack of
genotyping data on additional SNPs. These results will
need to be replicated with more SNPs in larger sample
sizes and cohorts with more comprehensive measurements to fully substantiate and support the hypothesis
proposed. This is the first study investigating genetic
associations of IL6 SNPs with obesity, obesity-related
inflammation and metabolic syndrome in an understudied
population of Mexican-Americans from South Texas.
Because of the complexity of IL6 regulation in obesity
and obesity-related inflammation, further research needs
to be conducted to investigate the myriad cellular and
molecular pathways affected by the IL6 polymorphisms.
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